The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS
Abstract
In Brief Purpose: Ranibizumab (Lucentis) is a humanized antigen-binding fragment designed to inhibit all isoforms and active degradation products of vascular endothelial growth factor A (VEGF-A); it is in clinical development for the treatment of neovascular age-related macular degeneration (AMD). This study evaluated its pharmacokinetics (PK) and retinal distribution in rabbits when administered intravitreally (ITV). Methods: A total of 27 New Zealand white rabbits received a single bilateral ITV injection of ranibizumab 625 μg/eye (Group 1, n = 24) or 125I-labeled ranibizumab 625 μg/eye, 22.5 μCi/eye (Group 2, n = 3). Ranibizumab concentration was determined in the vitreous, aqueous humor, and serum up to 60 days postdose by enzyme-linked immunosorbent assay in Group 1. Group 2 eyes were microautoradiographed on days 1–4. Results: Ranibizumab has a terminal half-life of 2.9 days in the ocular compartments. Systemic exposure was low, measuring less than 0.01% of vitreous exposure when comparing AUC0-t values. Microautoradiography analysis demonstrated that ranibizumab penetrated all retinal layers, reaching the choriocapillaris on days 1, 2, and 4. Conclusions: This study demonstrates that following ITV injection, ranibizumab has a vitreous half-life of 2.9 days with minimal systemic exposure. Ranibizumab rapidly penetrates through the retina to reach the choroid, supporting its clinical development for neovascular AMD. This non-clinical study in rabbits demonstrates that following intravitreal injection, ranibizumab, a humanized antigen-binding fragment against vascular endothelial growth factor A, has a vitreal half-life of 2.9 days with minimal systemic exposure and that it rapidly penetrates through the retina to reach the choroid, supporting its clinical development for neovascular age-related macular degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Cited by
Sun, X., Yang, S., & Zhao, J. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97653 · Cited by 347
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature
Stanescu-Segall, D., Balta, F., & Jackson, T. L. (2016) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.04.004 · Cited by 175
Maguire, M. G., Daniel, E., Shah, A. R., Grunwald, J. E., Hagstrom, S. A., Avery, R. L., Huang, J., Martin, R. W., Roth, D. B., Castellarin, A. A., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.017 · Cited by 93
Direct Comparison of Administration Routes for AAV8-mediated Ocular Gene Therapy
Igarashi, T., Miyake, K., Asakawa, N., Miyake, N., Shimada, T., & Takahashi, H. (2013) · Current Eye Research · doi:10.3109/02713683.2013.779720 · Cited by 64
Metadata
- Authors
- GAUDREAULT, J., FEI, D., BEYER, J. C., RYAN, A., RANGELL, L., SHIU, V., & DAMICO, L. A.
- Venue
- Retina
- Published
- 2007-11
- Volume
- 27
- Issue
- 9
- Pages
- 1260-1266
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2091929661
- Cited by
- 181
- References
- 2
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS. https://app.cochat.ai/papers/10.1097/iae.0b013e318134eecd
- The paper
- GAUDREAULT, J., FEI, D., BEYER, J. C., RYAN, A., RANGELL, L., SHIU, V., & DAMICO, L. A. (2007). PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS. Retina. https://doi.org/10.1097/iae.0b013e318134eecd
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.